Get started

Stocktrading

AMD to $200 (61%) – Strong Support ends ConsolidationNASDAQ:AMD weekly charts looks very good. The trendline from March 2023 is intact and we also touched the 61.8 fibonacci from the complete move (starting in October 2023). The descending wedge could be broken to the upside today, which would be a bullish sign for a stronger move towards $200. All in all, many semiconductor stocks are currently on supports or are fundamentally more attractive than they were months ago. Fundamentally NVIDIA still dominates the AI datacenter market with a market share of over 90%. But Advanced Micro Devices is improving its hardware and software offerings. The recently released MI325X and the upcoming MI350 series could give AMD more market share with faster release cycles. First signs show significant customer interest. In addition, AMD has a more stable revenue stream from other products like CPUs and non-AI datacenters. Given the high prices of NVIDIAs products the market itself should have a deeper interest in more competition. Target Zones $135 $160 $200 Support Zones $117-$120
NASDAQ:AMDLong
by LGNDRY-Capital
1
#NAS100USD 4HNAS100USD (4H Timeframe) Analysis Market Structure: The price is consolidating within a symmetrical triangle pattern, indicating indecision in the market. This pattern reflects a balance between buyers and sellers, with the potential for a breakout in either direction. Forecast: A breakout on either side of the triangle will determine the next directional move. Traders are advised to wait for confirmation before entering a position. Key Levels to Watch: Entry Zone: Wait for a confirmed breakout above the resistance or below the support of the triangle. Risk Management: Stop Loss: Placed beyond the opposite side of the breakout to manage risk. Take Profit: Target measured moves based on the height of the triangle, projected from the breakout point. Market Sentiment: The symmetrical triangle suggests neutral sentiment, with the potential for significant movement depending on the breakout direction.
OANDA:NAS100USD
by PIPSFIGHTER
PALANTIR: 1st test of the 1D MA50 since August. Is it a BUY?Palantir has turned bearish on its 1D technical outlook (RSI = 42.953, MACD = 2.150, ADX = 40.007) as it almost touched the 1D MA50 today for the first time in 5 months. The last time it was under it was on the August 5th low (which was supported by the 1D MA200) and is practically the trendline that helped the stock go parabolic inside the curved channel you see on the chart. Even if the 1D MA50 marginally breaks, the trend will stay bullish as long as the RSI S1 Zone supports. Until it breaks, we will stay bullish on PLTR, expecting the parabolic channel to make at least one more bullish wave, aiming for a standard +60% rise (TP = 100.00). ## If you like our free content follow our profile to get more daily ideas. ## ## Comments and likes are greatly appreciated. ##
NASDAQ:PLTRLong
by InvestingScope
Trading in My PJs: How Comfort Turned My Trading AroundI used to think you had to look the part to be a serious trader - suit up, stare at screens in some office-like setting, and wear that intense Wall Street frown. But one chilly morning, I decided to ditch the suit for my pajamas, and guess what? It was one of the best moves for my trading career. The Day Comfort Clicked Waking up to the cold, I chose to trade from my cozy bed, PJ's on, with a warm cup of tea instead of my usual coffee. Something amazing happened right then. I felt so relaxed, the stress of trading just melted away, and suddenly, my decisions were clearer. I started catching trends I would've missed in my buttoned-up days, and my performance? It just took off. How Comfort Changed My Trading Trading from the comfort of my own bed or a comfy chair did more than just feel good: -Stress Vanished: Being in a chill environment made me less worried about market swings, leading to more thoughtful calls. -Sharper Focus: Without the itch of a stiff shirt or the squeeze of a tie, I could zone in on those charts for hours, picking up on patterns I'd usually miss. -Smarter Risk Management: Feeling at ease meant I stuck to my trading plan better, dodging those impulsive trades that often left me in the red. Making Comfort Work for Me It wasn't just about chilling out all day. Here's how I mixed comfort with keeping my game tight: -My Trading Nook: I made a little corner in my room my trading spot, with all my gear handy, but with that homey, warm feel. -Sticking to a Schedule: Even in my pajamas, I kept things structured, starting with a quick workout to get my brain going, then trading with the same focus as if I were at work. -Mindset Shift: I treated my comfy setup like a professional space, ensuring I was not just trading but also learning and growing. What I Took Away The big lesson? Your surroundings play a huge role in your trading psychology. A bit of comfort can lead to a calmer, smarter approach to the markets. It's not about slacking; it's about setting up the perfect mental space for making wise choices. Are You Trading Uncomfortably? If you're still in an uncomfortable setup, thinking formality equals seriousness, maybe it's time to reconsider. Comfort could be your trading edge. Finding That Balance Of course, there's a balance to strike. While trading in PJs can be a game-changer, you still need discipline, to stay informed, and dive into market news. If you're curious about blending comfort with trading discipline or if your setup's not cutting it, shoot me a DM. I've walked this path, and I'm here to help you find what clicks for you too! Kris/Mindbloome Exchange
TVC:GOLDEducation
by Mindbloome-Trading
My Fitness Journey: How Hitting the Gym Upped My Trading GameThere was a time in my trading journey when I thought that focusing solely on numbers, charts, and the next big trade was the way to go. But honestly, I was burning out, feeling foggy, and my health was taking a backseat. That all changed when I decided to swap my late-night snacks for a gym membership. The Day It Hit Me: I'll be real with you; I started working out not for the six-pack but because I needed to clear my head and get some energy back. And wow, did it ever transform my trading game. I've got the charts to prove it - my trading performance before and after getting fit. Before, I was missing opportunities, getting stressed, and making rash decisions. Now, I'm more alert, my timing's spot-on, and my risk management? It's like night and day. What Being Out of Shape Does to You I did some digging, and there's actual science behind why this works. Exercise gets your brain firing on all cylinders, making you better at those quick, critical decisions we face every trading day. It's not about becoming a bodybuilder; it's about getting your blood pumping to where it counts - especially your brain. How I Got My Groove Back I'm not saying you need to live at the gym. My routine's simple; I do what I can even while the markets are buzzing. A quick morning workout or some stretches during lunch breaks has made all the difference. It’s all about finding that sweet spot, where you're not just a trader but a healthy human being too. What I Learned from All This This journey's been an eye-opener. I realized that being a good trader isn't just about knowing the market; it's about knowing yourself. This wasn't just about sharing data; it was about sharing a piece of my life, hoping it echoes with you. It's sparked so many chats because, let's be real, we all struggle with keeping our health in check while chasing those green candles. Are You Trading While Unfit? The timing was perfect. With everyone talking about burnout and how to stay sharp, my story about how fitness upped my trading game felt like a message that needed to be out there. Whether you're into stocks, crypto, or forex, here's the deal - your health directly impacts your wealth. If you’re stuck or want to chat about juggling trading with a healthy lifestyle, hit me up with a DM. I’ve walked this path, and I’m here to lend a hand! Kris/Mindbloome Exchange
NASDAQ:DJTEducation
by Mindbloome-Trading
NVDIA: Is this post-CES correction THE buy opportunity of 2025?NVDIA turned from bullish to marginally neutral on its 1D technical outlook (RSI = 54.243, MACD = 1.190, ADX = 26.850) as despite yesterday's big rise ahead of the CES (Consumer Electronics Show) event, it got sold straight after the opening today. CEO Jensen Huang unveiled the firm's next-generation of gaming chips and pledged the "ChatGPT moment for general robotics is just around the corner". Fundamentals aside, the technical price action is clear. NVDIA reclaimed the 1D MA50, a key level during both early 2024 and 2023 rallies. Technically we can argue that this is the best opportunity to buy in 2025, despite being so early. The reason is that both in 2024 and 2023, the lowest level to buy was again in early January. In both instances the stock started a rally and never saw lower prices again. Of course this is to a larget extend due to the long term pattern, which is a Channel Up since the October 2022 bottom. The sequences followed inside this pattern have been identical and so far October 2024 and January 2025 shares the same characteristics: keeping the 1D MA200 intact as the main support and the 1D MA50 contact being a buy signal. The post January rallies scored over a +100% increase, lasting around 95 days. Consequently, if the pattern continues to hold, we can aim for 250.00 by the end of March 2025. Today's correction may very well be the best buy opportunity for NVDIA for the whole year. ## If you like our free content follow our profile to get more daily ideas. ## ## Comments and likes are greatly appreciated. ##
NASDAQ:NVDALong
by InvestingScope
4
How to Analyze a Stock ? Key Questions to Ask Before You InvestShould I invest in this stock ? This is a common question investors face many times But where do you begin? What should you look for, and what pitfalls should you avoid? This guide will walk you through the essential steps to analyze a stock, focusing on the business itself rather than the stock chart. Since earnings per share (EPS) growth drives returns, it’s crucial to understand how revenue growth and margin expansion contribute over time. Before buying any stock, ask yourself these six critical questions: 1.Company: What does the business do? 2.Economics: How does it generate revenue? 3.Opportunities: What are the potential upsides? 4.Risks: What challenges could it face? 5.Financials: What do the numbers reveal? 6.Valuation: Is the price justified? 1.What’s the Business? - Mission: A clear mission drives long-term success. For example, Google’s mission, “to organize the world’s information and make it universally accessible and useful,” is simple yet powerful. Does the company’s mission align with a growing trend or an unmet need? - Leadership: Effective leadership, especially from founder-led teams or CEOs with a strong track record, often outperforms. Assess the team’s vision, execution skills, and employee approval ratings. - Products: Are the company’s offerings essential, innovative, or part of a growing market? Consider their uniqueness, potential obsolescence, and innovation history. 2.How Do They Make Money? - Revenue Mix: Is the company’s revenue diversified or reliant on a single product or customer? A diverse mix offers stability, while over-reliance can be risky. - Unit Economics: Examine profitability metrics like gross margin and operating margin. Where does the bulk of profit come from? - Key Metrics: Identify metrics like annual recurring revenue (ARR) for subscriptions or gross merchandise value (GMV) for e-commerce that best reflect the company’s performance trends. 3.What Could Go Right? - Market Growth: Does the company operate in a growing industry, such as AI or renewable energy? -Innovation: Look for ongoing R&D and a track record of successful product launches. -Moat Expansion: Assess the company’s competitive advantage, whether it’s a strong brand, proprietary technology, or cost leadership. 4. What Could Go Wrong? -Market Disruption: Is the company prepared for sudden changes, like new technologies or regulations? -Competition: Strong rivals can erode market share. Analyze customer reviews and competitor benchmarks. - Moat Erosion: A shrinking competitive edge—such as declining pricing power or poor retention—can signal trouble. 5.What Do the Numbers Say? - Profitability: Check revenue growth, gross margins, and net income for consistent improvements. - Solvency: Assess the balance sheet for debt-to-equity ratios, cash reserves, and financial stability. - Liquidity: Positive and consistent cash flow indicates sustainability and growth potential. 6.Is the Price Right? - Valuation Metrics: Use Price to Earnings (P/E), Price to Sales (P/S), or other relevant metrics depending on the company’s growth stage. Compare these to peers and market standards. -Investment Horizon: Longer investment timelines can justify higher valuations if growth potential exists. -Focus on Fundamentals: Valuation matters only if the business is strong. Avoid being tempted by low prices without underlying value. By breaking a company into these six dimensions, you can turn complex decisions into actionable insights. Start with the business fundamentals, evaluate opportunities and risks, and finish by assessing valuation. What stock will you analyze next? Let’s put this framework into action now
NASDAQ:NVDAEducation
by moonypto
Why You Shouldn't Be a Trader: The Emotional RollercoasterEver thought about diving into trading? Here's the honest truth from someone who's been there. I used to think trading was all about numbers and charts, but boy, was I wrong. It's more like riding an emotional rollercoaster that can make you feel like you've aged years in a single day. Imagine this: one day you're on top of the world, feeling like you've finally figured it out, and the next, you're down in the dumps, rethinking your entire life. Here's the deal: -Heart-Stopping Volatility: The market's ups and downs can turn your emotions upside down. One second you're ecstatic with a win; the next, you're in despair over a loss. -No Off Switch: Unlike most jobs, there's no "clocking out" with trading. Your mind never really stops, even when you're supposed to be chilling. -The Lonely Trader's Path: It can feel like you're on this journey alone, with no one to share the load or celebrate the victories with. But here's the twist - I've learned how to navigate this wild ride. With a bit of community and some laughs, trading doesn't have to be a solo act. If you're feeling the weight of this rollercoaster or just curious about how to keep your emotions in check, why not hit me up? Drop me a DM or check out my profile for more on how we can tackle this together. Give this post a boost, a like, or leave a comment if you've felt the same way. Let's share the journey, not just the journey's lows. Kris/Mindbloome Exchange Trade What You See
SP:SPXEducation
by Mindbloome-Trading
Trading Anxiety: When Fear Messes Up Your TradesEver had that scary feeling in your tummy before you make a trade? I totally get it. I used to let my worries take over my trading days. Every time the market went down, it felt like it was out to get me, making me sell stuff too fast or miss out on good deals because I was too scared. Here's what happened: - Always Scared: I was so afraid of losing money that I kept questioning every move I made, even when it was probably the right one. - Stuck in Thinking: I'd look at so many charts that I couldn't make up my mind. It was like being stuck because every choice seemed like it could be wrong. - No Sleep: I thought staying up late to watch the markets would help me, but it just made me super tired and even more worried the next day. But I learned how to deal with it. I started using stop-losses, like safety nets, so I wouldn't lose too much. I tried mindfulness stuff to keep calm. And I decided no more screens after trading time, so I could get a good night's sleep. If you're feeling the same kind of worry when you trade, you're not by yourself. We're all in this together. Let's talk about how we can stay chill even when the market gets crazy. Leave a comment or send me a message if you want to chat about dealing with this stress. Kris/ Mindbloome Exchange Trade What You See
CRYPTO:PREUSDEducation
by Mindbloome-Trading
My FOMO Nightmare: How Missing One Trade Changed My Trading LifeI remember the day like it was yesterday. I was scrolling through X (Twitter), seeing everyone go wild over this one stock. My heart raced as I watched the price skyrocket, but I hesitated. I hadn't done my homework on this one, and something felt off. But the fear of missing out? That was eating at me. The next day, I woke up to see the stock had crashed. My initial relief turned into regret. Maybe I could've sold at the peak if I had just jumped in like everyone else. That's when FOMO, or Fear Of Missing Out, became my trading nemesis: -Hasty Actions: I started jumping into trades at the last minute, driven by the buzz on social media, not by my own analysis. -Screen Addiction: I couldn't step away from my screen, worried I'd miss the next big move. My life began revolving around the market's every twitch. - Chasing Losses: After missing a few opportunities, I found myself in a dangerous cycle, trying to make up for lost gains with even riskier trades. But here's the twist in my story. One evening, after a particularly bad day of chasing trends, I sat back and realized how this fear was controlling me, not my strategy. I decided to change. I set strict rules for myself: no trading based on social media hype, sticking to my research, and remembering that every market has its patterns - there's always another chance if you miss one. Now, I trade with a calm mind, knowing that if I miss one trade, there'll be another. If you've ever felt that burning desire to join the rush, only to regret it later, you're not alone. Let's share our stories and strategies for overcoming FOMO. DM me if you want to chat about how we can keep our heads in the game, not just our eyes on the screen. Kris/ Mindbloome Exchange Trade What You See
NASDAQ:METAEducation
by Mindbloome-Trading
AMD for STRONG buyWhy Buy AMD Stock? Market Leadership in Semiconductor Industry AMD is a globally recognized leader in the semiconductor industry, producing high-performance CPUs, GPUs, and adaptive computing technologies. Its innovative products cater to a wide range of markets, including gaming, data centers, artificial intelligence (AI), and embedded systems. Strong Financial Performance AMD has consistently demonstrated robust financial growth, driven by strong product demand, strategic acquisitions, and efficient cost management. Its competitive product lineup continues to drive revenue growth and profitability. Growing Market Opportunities The increasing adoption of AI, machine learning, cloud computing, and 5G technology creates a substantial growth opportunity for AMD's advanced processors and GPUs. The company is well-positioned to capture market share in these rapidly growing sectors. Innovation and Product Pipeline AMD’s commitment to innovation is evident in its cutting-edge product releases, such as the Ryzen series CPUs, Radeon GPUs, and EPYC processors. These products provide industry-leading performance and efficiency, making them highly sought-after in the technology market. Strategic Partnerships and Acquisitions AMD’s acquisition of Xilinx and strategic partnerships with industry leaders like Microsoft, Sony, and Amazon strengthen its product portfolio and expand its reach into new markets like JUST BUY AND HOLD.
NASDAQ:AMDLong
by Herkous
Urban Outfitters (URBN) AnalysisCompany Overview: Urban Outfitters NASDAQ:URBN is a prominent global lifestyle retailer, operating a diverse portfolio of brands such as Anthropologie, Free People, and Urban Outfitters. By embracing trends like sustainable fashion and enhancing omnichannel strategies, URBN demonstrates resilience and adaptability in a dynamic retail landscape. Key Catalysts for Growth Nuuly's Sustainable Fashion Success: Nuuly Rental Service: A 51% year-over-year growth in active subscribers showcases URBN's ability to align with consumer preferences for sustainable and flexible fashion. Capitalizing on the growing circular fashion economy, Nuuly strengthens URBN’s brand differentiation. Wholesale Segment Resilience: Despite industry headwinds, URBN’s wholesale segment posted a 3% revenue increase, reflecting operational agility and strong relationships with retail partners. Strategic Store Expansion: New store openings across global markets enhance URBN's reach, while strategically curated store experiences resonate with target demographics. Digital Innovation: Investments in e-commerce platforms and personalized online shopping experiences position URBN to capture a larger share of digital-first shoppers. Brand Diversification: Anthropologie and Free People continue to perform strongly, appealing to niche audiences and reducing reliance on a single revenue stream. Market and Financial Outlook Sustainable Fashion Momentum: As more consumers embrace rental and resale models, URBN is positioned to lead this shift, driving recurring revenue streams. Omnichannel Strength: With a robust digital presence complementing its physical stores, URBN is poised to capture growth in both online and in-store shopping segments. Investment Thesis Bullish Case: URBN’s focus on innovation, sustainability, and diversification enhances its competitive edge, making it well-suited for growth despite broader retail challenges. Entry Point: We are bullish on URBN above $47.00-$48.00, supported by strong technical indicators and a resilient business model. Upside Target: Our price target is $78.00-$80.00, reflecting confidence in URBN's ability to sustain growth and capitalize on emerging retail trends. 🌟 URBN—Innovating Retail, Driving Sustainable Growth. #FashionInnovation #Sustainability #OmnichannelRetail
NASDAQ:URBNLong
by Richtv_official
Trading Forex vs Stock CFDs: Differences and AdvantagesTrading Forex vs Stock CFDs: Differences and Advantages Forex and stock markets are two of the most popular options for traders, each offering unique opportunities and challenges. While forex focuses on trading global currency pairs, stocks involve buying and selling shares of companies. Understanding their differences—from market size and liquidity to trading costs and risk—can help traders choose the market that best suits their strategy. Let’s break down the key differences between forex and stocks. What Is Forex Trading vs Stock Trading? Let us start with some general information that you may already know. The forex market revolves around trading currency pairs, such as EUR/USD, and operates globally, making it the largest financial market with a daily turnover exceeding $7.5 trillion (April 2022). It’s decentralised, meaning transactions occur directly between participants across time zones, with no single central exchange. In contrast, the stock market involves buying and selling shares of publicly listed companies, like Tesla or Nvidia, through centralised exchanges such as the NYSE or LSE. Trading hours are fixed and tied to each exchange’s location, creating more defined trading windows. Forex markets are driven by macroeconomic events and international factors, while stocks are mostly influenced by company-specific developments like earnings reports and industry trends. In this article, we will talk about Contracts for Difference (CFD) trading. To explore live forex and stock CFD trading opportunities, head over to FXOpen’s free TickTrader platform. Forex vs Stock Trading: Market Accessibility and Trading Hours One of the most important differences between forex and stock markets is their structure and timings. Forex: Open 24/5 The forex market operates 24 hours a day, five days a week, cycling through major trading sessions in Sydney, Tokyo, London, and New York. This continuous nature allows traders to react to global events in real-time, whether it’s midday in the UK or midnight in Asia. For example, a trader monitoring the London session can seamlessly transition into the New York session without waiting for markets to reopen. Stocks: Fixed Timeframes Stock trading is tied to the operating hours of centralised exchanges. For example, the NYSE runs from 9:30 am to 4:00 pm EST, while the LSE operates from 8:00 am to 4:30 pm GMT. This also applies to stock CFDs. Outside of these hours, activity is limited to pre- and post-market trading, which typically sees lower liquidity and higher spreads. Conclusion Forex provides flexibility for traders who value around-the-clock access, while stock traders need to plan their activity within set hours. This makes forex especially appealing to those with unconventional schedules or a need for an immediate market response. Trading Stocks vs Forex: Market Size and Liquidity The size and liquidity of a market dictate how efficiently trades are executed and at what cost. Forex and stock trading differs significantly in these areas. Forex: The $7.5 Trillion Giant The forex market stands as the largest in the financial world, with daily trading volumes exceeding $7.5 trillion (April, 2022). This immense size ensures high liquidity in many pairs, meaning they can be traded almost instantly with minimal price slippage. Tight spreads—often as low as fractions of a pip—make forex particularly attractive to traders seeking frequent, precise entries and exits. Stocks: Liquidity Highly Varies The stock market is smaller and is subject to more complicated factors, therefore, traders may suffer when opening and closing trades. First, stock liquidity highly depends on the company and its trading volume. Blue-chip stocks like Apple or BP typically offer high liquidity, which contributes to smooth transactions with competitive spreads. However, smaller, less-traded stocks may suffer from wider spreads and slower execution, particularly during market volatility. Second, trading hours affect market liquidity, making it challenging to trade before and after market close. Conclusion Forex’s unmatched liquidity mainly ensures consistent trade execution across major pairs. In contrast, stock traders must carefully choose assets to avoid issues with low liquidity, especially when trading small caps or during off-peak hours. Forex vs Stocks: Volatility and Price Drivers High volatility creates opportunities for traders by producing price swings that can be capitalised on. However, the factors driving these movements differ significantly between forex and stocks. Forex: Global Events and Macro Trends Forex volatility is often driven by large-scale economic and geopolitical events. Central bank interest rate decisions, employment data, inflation reports, and geopolitical tensions can cause significant price shifts. For instance, a hawkish Federal Reserve announcement can lead to USD appreciation against other currencies. Currency pairs also experience varying levels of volatility depending on their classification. Major pairs like EUR/USD tend to be less volatile than exotic pairs such as USD/ZAR, where price swings can be much more dramatic due to lower liquidity and heightened economic risks. Stocks: Company-Specific Drivers Stock volatility is more granular, often linked to specific companies. Earnings reports, mergers, leadership changes, or industry news can move a single stock significantly. Broader market trends, such as sector-wide sentiment shifts, can also drive volatility, but these are secondary to company-specific factors. For example, Tesla’s earnings announcement can cause sharp movements in its share price without impacting other automakers. Conclusion Forex volatility is broader and influenced by global macroeconomic trends, while stocks are typically driven by isolated, company-specific events. This distinction makes forex appealing for traders focusing on macro analysis and technical patterns, whereas stock traders often blend fundamental company research with broader market trends to identify trading opportunities. Forex Trading vs Stock Trading: Trading Costs and Leverage Trading costs and leverage significantly impact a trader’s strategy and potential returns. And choosing between trading stocks or forex is no exception. Forex: Potentially Low Costs and High Leverage Forex may provide opportunities for lower-cost trading, with fees paid via commissions and spreads. For instance, forex commissions at FXOpen start at $1.50 per lot, depending on account size. Spreads are usually tight for major pairs like EUR/USD, making costs relatively low. At FXOpen, you can trade with spreads from 0.0 pips. Forex offers significantly higher leverage compared to stocks. While this allows traders to operate with smaller capital, it requires disciplined risk management to avoid significant losses. Stocks: Higher Costs, Lower Leverage Stock trading via CFDs typically incurs higher costs compared to forex, with commissions charged per trade or embedded in spreads. For instance, at FXOpen, US stock CFD traders can see commissions charged from 0.04% to 0.1%, varying by account size, with a minimum commission of $1 per order. Leverage is also lower—usually capped at 1:5 for retail traders, reflecting the relative instability of stock prices compared to currencies. Conclusion Forex CFDs offer lower costs and higher leverage, making it popular among traders with a short-term focus. Stock CFDs, while more expensive, give access to financial instruments for portfolio diversification. Choosing between them depends on the trader’s goals, risk tolerance, and preferred market dynamics. Forex vs Stocks: Regulation and Market Transparency Regulation and transparency are critical for traders when choosing between forex and stocks. Both markets are regulated, but their structures create distinct differences in how pricing and trade execution work. Forex: Decentralised and Broker-Driven The forex market is decentralised, meaning trades are executed through brokers rather than central exchanges. This structure can lead to variations in pricing and execution quality, depending on the broker. Therefore, traders need to find regulated brokers to avoid issues with unreliable pricing or execution. For example, FXOpen is regulated by the FCA and CySEC to ensure fair practices and client fund protection. Stocks: Centralised and Transparent Traditional stock markets operate on centralised exchanges like the NYSE or LSE, where all trades are matched through a regulated order book. This ensures consistent pricing and high transparency, as traders can see bid and ask levels across the market. At the same time, stock CFDs are traded on a broker level. Conclusion Forex and stock CFDs’ decentralised nature provides flexibility but relies heavily on broker reliability. Forex Trading vs Stock Trading: Suitability for Different Trader Types Deciding between forex trading and stock trading comes down to choosing between each market’s unique characteristics. Forex: Favouring Short-Term Strategies Forex is ideal for short-term traders, such as scalpers and day traders. Its high liquidity and round-the-clock trading mean there’s always an opportunity to act on price movements, especially during overlapping sessions like London and New York. The use of leverage, often higher in forex, makes it appealing for those seeking to amplify returns on smaller price shifts (please remember that higher leverage leads to higher risks). Traders in forex often focus on technical analysis, utilising chart patterns and indicators, and study macroeconomic data to analyse short-term trends. This market tends to suit individuals who are comfortable with frequent decision-making and quick trade execution. Stocks: A Blend of Short and Medium-Term Trading Stock trading, particularly via CFDs, is more versatile, attracting both medium-term and swing traders. While day trading is possible, the structured trading hours and broader price swings make stocks particularly appealing for those who prefer holding positions for days or weeks. Stock traders often lean on company-specific fundamentals, such as earnings reports or sector trends, alongside technical analysis. This market suits individuals who prefer analysing individual businesses or sector dynamics over global macro trends. Conclusion Forex trading caters to short-term strategies, attracting traders who thrive on quick decisions and frequent trades, while stock trading offers flexibility, appealing to those who prefer a mix of short- and medium-term strategies with a focus on company fundamentals. Each market has unique characteristics, allowing traders to choose based on their style and objectives. The Bottom Line Both forex and stock markets may offer unique opportunities tailored to different trading strategies and goals. Whether you’re drawn to forex’s 24/5 accessibility or the structured transparency of stocks, understanding their key differences is crucial. Ready to explore forex and stock CFD trading? Open an FXOpen account today and take advantage of competitive spreads, fast execution speeds, and a wide range of instruments. FAQ Is the Stock Market Bigger Than Forex? No, the forex market is significantly larger. Forex sees daily trading volumes exceeding $7.5 trillion (April, 2022). This makes forex the largest and most liquid market, popular among traders seeking tighter spreads and fast execution. What Is the Correlation Between Forex and Stock Markets? The relationship varies. Commodity-linked currencies like AUD or CAD often correlate with related stocks or indices. Broader market sentiment, such as risk-on or risk-off conditions, can also drive both forex and stocks in similar or opposing directions. Should I Invest in Forex or Stocks? It depends on your trading style. Forex could suit short-term traders focusing on global economic trends, while stocks might appeal to those who prefer company analysis or medium-term strategies. Which May Offer Greater Returns, Forex or Stocks? Ultimately, potential returns depend on your strategy and discipline. Forex offers higher leverage for short-term trades, but higher leverage leads to higher risks. Stocks may provide better longer-term growth potential, but they are subject to high volatility. Which Is Riskier, Forex or Stocks? Forex can be riskier due to leverage and rapid price swings. Stocks also carry risks, particularly from company-specific events, but lower leverage makes losses potentially less amplified. The risk depends on your approach and management. This article represents the opinion of the Companies operating under the FXOpen brand only. It is not to be construed as an offer, solicitation, or recommendation with respect to products and services provided by the Companies operating under the FXOpen brand, nor is it to be considered financial advice.
Education
by FXOpen
2
Suntek realtyFrom the Covid low of 145 zone prices have given a rally for two years and made a high of 590 in Jan'22. From there prices have retraced 50% and made a low of 272 and recovered back to hit new all time high. Prices have made a continuation Head & shoulders pattern whose neckline is 500 zone. Prices have given the breakout the neckline and currently retesting the same. The measured target of the pattern is 950 zone. Prices are likely to continue the uptrend towards 950-1000 zone in the coming months. The key level for the same is 380.
NSE:SUNTECKLong
by TradingSutra
Linde plc | LIN Linde, Timeless Excellence Linde is a timeless business with even better stability than other basic materials businesses. The company works in gases and has a near-unbroken EPS growth record of 8% annually Linde is a market leader, and if you invest in the company, you're investing in the world's largest company for industrial gases. The company was originally a result of a takeover of British BOC in 2006, and again the 2018 merger of Linde and Praxair, a US company. On the macro upside, there was a 1) supportive regulatory framework in the USA and in the EU on green opportunities and hydrogen, 2) the Ukraine invasion was also a key catalyst towards the energy transition, 3) the EU chip acts with €43 billion in supporting funds as well as the United States Chips and Science Act development for a value of approximately $52 billion, and 4) higher needs of specialty gas in EV car. Related to the micro upside, the company is more diversified on a GEO revenue basis and sells different product solutions starting from cylinders to bulk liquid. In addition with a follow-up note titled "Positive News Ahead", we reported Linde's lower cost structure with the Frankfort delisting. Aside from removing the dual listing expenses, we positively view this development because US companies' P/E multiple are usually higher compared to the EU one. To support our MACRO buy case recap, in the second quarter, Linde announced two new projects with Evonik and Heidelberg Materials (both companies covered by our internal team). The company signed a long-term agreement to produce green hydrogen for Evonik in a 9-megawatt alkaline electrolyzer plant in Singapore. With Heidelberg, Linde will build a large-scale carbon capture close to the Lengfurt plant in Germany. As a reminder, cement production is estimated to be responsible for around 7% of global in 2022, APD's earnings per share were at $8.38, and Linde's earnings per share were fairly similar at $8.23. For 2023, Air Products and Chemical EPS guide a midpoint at $11.40 while Linde's EPS is forecasted at $13.65. Looking at the ROCE, in Q4 2022, APD stood at 11.7% and Linde at 13.4%. In the last quarter, APD’s ROCE was flat on the two-year comparison, while Linde’s after-tax ROCE reached 24.0%. While there are some business & regional nuances between the two leading companies (for instance, APD is lacking U.S. packaged gas business), here at the Lab, we believe are more inclined toward Linde, particularly when organic growth has been fairly similar. Cross-checking APD and Linde's last quarter results, we should recall that on a comparable basis, the German player volumes were flat with an average selling price up by 8%. On the other hand, APD increased its volume by 6% with an increase in the average selling price of 8% too. APD adj EBITDA grew by 13% while Linde achieved a plus 11%. However, Linde's EU exposure is greater than APD. Therefore, this is supportive of Linde's bottom line. In numbers, excluding the Engineering divisional performance, Linde's EMEA sales reached $2,177 million and represented 29.72% of the company's total sales. Compared to Q1 2022 number, turnover grew by 10% and was driven by a 13% of cost pass-through increase.
LLong
by moonypto
6
Shopify Inc | SHOP & AIShopify stock has seen sideways momentum for the last few weeks despite posting good results in the recent quarter. One of the reasons is the bull run in early 2023 due to which the stock has seen over 60% jump in year-to-date. Shopify has been able to reignite revenue growth in the last few quarters and there are strong tailwinds that can help the company improve its topline. At the same time, Shopify has been able to improve the conversion of Gross Merchandise Value or GMV into revenue due to better services. Shopify’s GMV has increased 11x between the last quarter of 2016 and the last quarter of 2022. During this time, Shopify’s quarterly revenue base has increased from $130 million to $1.7 billion or 13x. Shopify’s GMV for 2022 was $195 billion and rapid growth in this key metric should help the company improve monetization. The company has also undertaken some cost-cutting which is having a positive impact on the bottom line. Analysts have forecasted Shopify’s EPS at $1 for fiscal 2025 which means that the stock is trading 60 times the EPS estimate of 2025. However, better monetization and focus on cost optimization could help the company deliver good EPS growth in the next few quarters. The PS ratio is also at 12 which is significantly lower than the pre-pandemic years. Shopify stock can deliver good returns in the long term as the company adds new services and improves its GMV growth trajectory. Shopify reported a GMV of $5.5 billion in December 2016 quarter. This has increased to $60 billion in the recent December 2022 quarter. Hence, Shopify’s GMV has increased to 11 times within the last seven years. On the other hand, Shopify’s revenue during the December quarter has increased by 13 times, from $130 million to $1.7 billion. This growth trend shows that the company is able to convert more GMV into actual revenue. One of the main reasons behind this trend is that Shopify is adding new services and it can charge customers a higher commission for these services. Shopify’s GMV for 2022 was a staggering $195 billion. The company has been able to reignite revenue growth in the last few quarters. The YoY revenue growth hit a bottom of 15% in June 2022. Since then the YoY revenue growth has picked up again as the company faces easier comps. In the recent quarter, the company reported YoY revenue growth of over 30% which is quite high when we consider that the GMV base of Shopify is more than $200 billion. The revenue growth will not build a bullish momentum for the stock unless the company can deliver sustainable profitability. During the pandemic years, Shopify’s revenue growth and high EPS helped the stock reach its peak. The company would need to focus on profitability in the next few quarters in order to rebuild a long-term bullish rally. Shopify has divested from its logistics business which should help improve the bottom line. We should also see better monetization of current services as the company tries to build new AI tools. The EPS estimates for 2 fiscal years ahead have steadily improved in the last few quarters. According to current consensus, Shopify should be able to deliver EPS of $1 in fiscal year 2025. However, it is highly likely that Shopify will beat these estimates as the company launches new initiatives to improve monetization of its massive GMV base. Shopify’s trailing twelve months EPS during the peak of the pandemic went to $2.6. If the company can get close to this EPS rate by 2025, we should see a significant bullish run in the stock. The recent cost-cutting should also help the company improve the bottom line. We have seen a similar trend in all the Big Tech companies who have reported a rapid growth in EPS as their headcount was reduced. While most analysts agree over the long-term revenue growth potential of Shopify, some of them are wary of the pricey valuation of the stock. Shopify is trading at 12 times its PS ratio. This is quite high when we compare with most of the other tech players and even Shopify’s peer like Wix (WIX), Etsy (ETSY), and others. However, it should be noted that Shopify’s PS ratio is significantly lower than the average PS multiple prior to the pandemic when the stock had an average PS ratio of over 20. Shopify’s revenue estimates for 2 fiscal years ahead is close to $10 billion which is equal to annualized revenue growth of over 25%. If we look at this metric, Shopify stock is trading at 7 times the revenue estimate of fiscal year 2025. This looks reasonable if the company can also manage to improve its EPS trend over the next few years. The long-term tailwind from ecommerce growth is still very strong. Shopify will benefit from an increase in GMV and a higher ecommerce market share in key markets. This should help the company gain pricing leverage over other competitors and also improve its monetization momentum Shopify has reported a faster revenue growth rate compared to its GMV growth in the last few years. This shows that the company is able to charge higher rate for additional services. There has been an acceleration in revenue growth over the last few quarters. Shopify has also divested from logistics services which were pulling down the profitability of the company. Shopify could deliver over 20% YoY revenue growth for the next few years as the company gains from strong tailwinds within the ecommerce business. If Shopify regains its earlier ttm EPS of $2 by 2025, we could see a strong bull run within the stock. While the stock is not cheap, it seems to be reasonably valued and longer-term investors could gain a better return from Shopify, making the stock a Buy at current price.
NYSE:SHOPLong
by moonypto
2
TEVA Pharmaceutical is a BUY?As the excitement around AI continues to wane, concerns about a potential US recession grow, and the risks of a major conflict in the Middle East linger, Teva Pharmaceutical's stock is entering an accumulation phase above $18, signaling strong bullish sentiment. Why Wall Street's bullish in this drug company ? First, on July 31, Teva announced its financial results for the second quarter of 2024, demonstrating that the company remains resilient despite years of investor disappointment following the Allergan Generics acquisition and the loss of Copaxone exclusivity. However, over the past 18 months, under Richard Francis' leadership, the company has shown significant growth, with increasing revenue and profits in its European and US segments, the successful launch of biosimilars and Uzedy, and record sales of Austedo, its blockbuster treatment for certain neurological disorders. Alongside rising sales of generics, Teva has also accelerated the development of innovative medications, which could set new standards in treating schizophrenia and some chronic inflammatory diseases. For instance, on July 25, the company delighted investors by announcing that it had completed patient enrollment ahead of schedule in a Phase 2b clinical trial assessing the efficacy and safety of duvakitug for treating ulcerative colitis and Crohn's disease, driven by strong interest from healthcare professionals and patients. Teva Pharmaceutical's financial performance and 2024 outlook After years of challenges, the Teva revenue exceeded $4 billion once again, reaching $4.14 billion in the second quarter of 2024, a 7.4% year-on-year increase that surpassed consensus estimates by $114 million. Meanwhile, another critical financial metric, earnings per share aka EPS, exceeded my expectations despite rising costs associated with conducting expensive clinical trials for assessing the efficacy of Teva's biosimilars and experimental drugs targeting neurodegenerative and autoimmune disorders. The Israeli company's EPS reached $0.61 for the three months ending June 30, 2024, marking a 27.1% increase from the previous quarter and surpassing analysts' forecasts by six cents. What factors contribute to Teva Pharmaceutical's success? To answer this objectively, it's essential to examine not only the impact of sales from individual medications but also to delve deeper into how effectively the company's management is handling the development of each of Teva's business segments. We'll begin with the United States segment, which significantly influences Teva's financial standing. For the three months ending June 30, 2024, revenue in this segment reached $2.12 billion, reflecting an 11.5% year on year increase and a 22.3% rise from the previous quarter. First, Teva's revenue and profit growth were largely fueled by significant advancements in its generics business, despite facing stiff competition from companies like Viatris (VTRS), Dr. Reddy's Laboratories (RDY), Perrigo (PRGO), and others in the market. In the second quarter, total sales of generic products reached approximately $1.03 billion, marking a 26.6% increase from the previous quarter. What factors led to the recovery of Teva's generics business? The resurgence of Teva's generics business in the U.S. was primarily driven by the launch of an interchangeable biosimilar to AbbVie's Humira (ABBV), rising demand for generic versions of Bristol-Myers Squibb's Revlimid (BMY), a major blockbuster for treating multiple myeloma, the generic version of Novo Nordisk's Victoza (NVO) for type 2 diabetes, and the expansion of its drug portfolio. The soaring sales of Copaxone and the strong performance of Austedo, which I analyzed in detail in a previous article, were also notable. Despite increasing competition in the U.S. tardive dyskinesia therapeutics market from Neurocrine Biosciences' (NBIX) Ingrezza, Austedo's demand continued to grow. Sales of the Austedo franchise reached $407 million in the second quarter of 2024, a 32.1% YOY increase, driven by expanded patient access and the FDA's late May approval of Austedo XR in four new tablet strengths, giving doctors more options for optimizing treatment regimens for adults with tardive dyskinesia and Huntington's disease-associated chorea. I also want to highlight Uzedy, a long-acting formulation of risperidone, as another key contributor to Teva's revenue growth. Although the company launched Uzedy in May 2023 and has not yet disclosed its sales figures, it has been approved for the treatment of schizophrenia. However, as evident from the chart below, the total number of prescriptions has been steadily increasing month over month. Teva Pharmaceutical estimates that its revenue from Uzedy will be around $80 million in 2024, exceeding my expectations by approximately $25 million. Despite ongoing growth in demand for this anti-CGRP migraine medication, its sales amounted to $42 million in the second quarter of 2024, a decrease of 6.7% compared to the previous quarter and 19.2% year-on-year. This decline was primarily due to an increase in sales allowances linked to a one-time event. Now, let's turn our attention to the company's Europe segment, which generates most of its revenue through sales of generics and biosimilars. For the three months ending June 30, 2024, sales in this segment reached approximately $1.21 billion, reflecting a 4.3% year-on-year increase, driven by new product launches and growing demand for Ajovy. However, sales of respiratory medications continue to face challenges due to a decline in cold and flu cases. As anticipated, demand for Copaxone is weakening, not only because of competition from generic versions but also due to the availability of more effective treatments for relapsing forms of multiple sclerosis, such as Bristol-Myers Squibb's Zeposia, Roche Holding's Ocrevus and TG Therapeutics' Briumvi (TGTX). Lastly, let's discuss the International Markets segment, which focuses on commercializing Teva's drugs across 35 countries, including Canada and Japan. In the second quarter, revenue for this segment was $593 million, representing a 2.6% YOY increase. However, the segment's profit dropped significantly to $73 million quarter over quarter, due to declining demand for Copaxone, increased R&D expenses, and higher sales and marketing costs related to the distribution of Austedo in China. The question arises: "Are there any positives?" The short answer is yes. Teva's revenue from generic drugs has been on an upward trend in recent years, with the exception of the fourth quarter of 2023. For the three months ending June 30, 2024, it reached $488 million, marking a 2% increase from the previous quarter. What is driving this sales growth? Despite challenges such as the weakening of foreign currencies like the Japanese yen, ruble, and Chinese yuan against the US dollar, increased competition in Japan, and ongoing inflationary pressures on the pharmaceutical industry, Teva’s management has successfully navigated these obstacles by expanding its medication portfolio and raising prices. Now lets talk about Risks Several risks could negatively impact Teva Pharmaceutical’s investment appeal in the medium to long term. At the end of July, Teva reported financial results for the second quarter of 2024, which not only exceeded analysts' expectations but also reinforced confidence in the effectiveness of the business strategies implemented by CEO Richard Francis. In addition to accelerating the recovery of the company's generics business, boosting sales of Austedo and Uzedy, and launching the Humira biosimilar in May, Teva also raised its full-year 2024 guidance. With a P/E ratio of 6.35x, which suggests the stock is trading at a discount compared to the broader healthcare sector, other positives include the reduction of Teva’s net debt by about $2 billion over the past 12 months, as well as year-over-year growth in gross and operating profits. To understand who truly holds control over Teva Pharmaceutical Industries Limited, it's crucial to examine the company's ownership structure. The largest share of ownership, approximately 69%, is held by institutional investors. This means that this group stands to experience the greatest potential for gains or losses, depending on the company's performance. The company has also accelerated the development of its product candidates under its "Pivot to Growth" program, which aims to strengthen its balance sheet and enhance its investment appeal by expanding its biosimilar portfolio and bringing potential best-in-class drugs for cancer, neurological, and autoimmune disorders to market. So TEVA Pharmaceutical is a BUY? YUP
NYSE:TEVALong
by moonypto
Trading While Tired: How Lack of Sleep Messed Me UpThere was a time in my trading journey when I thought staying up late would make me a better trader. I’d sit at my desk until the early hours, staring at charts and telling myself, “The more I watch, the more I’ll win.” At first, it seemed like it was working. I caught a few decent trades late at night and felt like I was ahead of the game. But then, it all started to go wrong. The Day It Hit Me One morning, after getting just four hours of sleep, I sat down to trade like I always did. But something felt off. I couldn’t focus on the charts—I kept missing obvious patterns. On one trade, I completely forgot to set a stop-loss, and it ended up costing me more than it should have. By the end of the day, I had made so many mistakes that I didn’t even recognize myself as a trader. I was losing money, and I felt like a mess. What Lack of Sleep Does Looking back, I can see how skipping sleep was hurting me. Here’s what I went through: - I Couldn’t Think Clearly: I felt foggy and couldn’t concentrate on my trading plan. - I Made Bad Choices: I rushed into trades without thinking them through. - I Was Moody: Losing trades hit me harder than they should have, and little things made me angry. - I Drank Too Much Coffee: I thought caffeine would fix my tiredness, but it just made me jittery. - I Broke My Rules: I was too tired to follow my trading strategy. How I Fixed It One day, after another sleepless night and a morning full of mistakes, I decided enough was enough. I told myself I needed to change. The first step? Making sleep a priority. At first, it was hard to turn off the charts and go to bed. I thought I’d miss out on opportunities, but the truth was the opposite. With proper rest, I became sharper, calmer, and more confident in my trades. What I Learned -Sleep is as important as trading skills—you can’t think clearly without it. -Watching the charts all night doesn’t help if you’re too tired to make good decisions. -A good night’s sleep leads to smarter, more focused trading. Are You Trading Tired? If you’re staying up late and feeling exhausted while trading, it’s time to change that. Trust me, your trades will get better when your brain has the energy to work properly. If you’re stuck or want to chat about how to balance trading with a healthy lifestyle, send me a DM. I’ve been there, and I’m here to help! Kris/Mindbloome Exchange
KRAKEN:GALAUSDEducation
by Mindbloome-Trading
6
DJT: Will It Break $33.85 or $38.55 First? DJT is at a tipping point, and it could go either way. Here’s what to watch so you’re ready for the next big move. 1) If DJT Drops Below $33.85 If this level breaks, things could get rough. Here’s what might happen: -$28–$26: This is the first stop where the price might chill for a bit. -$10: If the selling gets heavy, this is where we could end up. 2) If DJT Pops Above $38.55 If the bulls take charge, it could be time to ride the wave higher: A break above $38.55 could spark a nice rally and push the price upward. What’s the Plan? -Keep an eye on $33.85 and $38.55—they’re the magic numbers. -Be patient and wait for a clear move before jumping in. If this makes sense, toss me a like or follow. Got questions about DJT or another stock you’re stuck on? Hit me up in the DMs—I’m here to help. And hey, if you’re feeling burned out or stressed about trading, let’s talk. I’m all about helping you find your balance and keeping things sustainable. Chill, stay focused, and let’s catch the next wave together! Kris/ Mindbloome Exchange Trade What You See
NASDAQ:DJT
by Mindbloome-Trading
2